EVMN
Evommune, Inc.
$26.33
-1.13%
2026-02-27
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Key Fundamentals
Forward P/E
-6.11
EPS (TTM)
$-11.22
ROE
-54.4%
Profit Margin
0.0%
Debt/Equity
1.00
Price/Book
3.60
Market Cap
$845.7M
Avg Volume (10D)
366K
Recent Breakout Signals
No recent breakout signals detected for EVMN.
Recent Price Range (60 Days)
60D High
$33.20
60D Low
$13.89
Avg Volume
598K
Latest Close
$26.33
Get breakout alerts for EVMN
Sign up for Breakout Scanner to receive daily notifications when EVMN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Evommune, Inc. (EVMN) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors EVMN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. EVMN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.